89Bio Inc
ETNB9.382USD
+0.222+2.42%
Horário de mercado （ET）Cotações atrasadas em 15 min
1.37BValor de mercado
PerdaP/L TTM
Mais detalhes de 89Bio Inc Empresa
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.
Informações da empresa
Código da empresaETNB
Nome da Empresa89Bio Inc
Data de listagemNov 11, 2019
CEOMr. Rohan Palekar
Número de funcionários93
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 11
Endereço655 Montgomery Street
CidadeSAN FRANCISCO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94111
Telefone14154329270
Sitehttps://www.89bio.com/
Código da empresaETNB
Data de listagemNov 11, 2019
CEOMr. Rohan Palekar
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Rohan Palekar
Mr. Rohan Palekar
Chief Executive Officer, Director
Chief Executive Officer, Director
312.57K
-51.62%
Mr. Quoc Le-Nguyen
Mr. Quoc Le-Nguyen
Chief Technical Operations Officer
Chief Technical Operations Officer
102.83K
-9.23%
Mr. Francis Willard Sarena, CPA., J.D.
Mr. Francis Willard Sarena, CPA., J.D.
Chief Operating Officer
Chief Operating Officer
78.75K
+215.00%
Mr. Ryan Martins
Mr. Ryan Martins
Chief Financial Officer
Chief Financial Officer
43.67K
-16.29%
Dr. Charles A. McWherter, Ph.D.
Dr. Charles A. McWherter, Ph.D.
Independent Director
Independent Director
25.00K
+150.00%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
Ms. Lota S. Zoth, CPA
Ms. Lota S. Zoth, CPA
Independent Director
Independent Director
--
--
Dr. Steven M. (Steve) Altschuler, M.D.
Dr. Steven M. (Steve) Altschuler, M.D.
Independent Chairman of the Board of Director
Independent Chairman of the Board of Director
--
--
Dr. Derek Paul Di Rocco, Ph.D.
Dr. Derek Paul Di Rocco, Ph.D.
Independent Director
Independent Director
--
--
Dr. Hank Mansbach, M.D.
Dr. Hank Mansbach, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Rohan Palekar
Mr. Rohan Palekar
Chief Executive Officer, Director
Chief Executive Officer, Director
312.57K
-51.62%
Mr. Quoc Le-Nguyen
Mr. Quoc Le-Nguyen
Chief Technical Operations Officer
Chief Technical Operations Officer
102.83K
-9.23%
Mr. Francis Willard Sarena, CPA., J.D.
Mr. Francis Willard Sarena, CPA., J.D.
Chief Operating Officer
Chief Operating Officer
78.75K
+215.00%
Mr. Ryan Martins
Mr. Ryan Martins
Chief Financial Officer
Chief Financial Officer
43.67K
-16.29%
Dr. Charles A. McWherter, Ph.D.
Dr. Charles A. McWherter, Ph.D.
Independent Director
Independent Director
25.00K
+150.00%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 12 de jul
Atualizado em: sáb, 12 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Janus Henderson Investors
14.02%
RA Capital Management, LP
13.62%
Suvretta Capital Management, LLC
9.82%
Deep Track Capital LP
6.38%
BlackRock Institutional Trust Company, N.A.
6.19%
Other
49.97%
Investidores
Investidores
Proporção
Janus Henderson Investors
14.02%
RA Capital Management, LP
13.62%
Suvretta Capital Management, LLC
9.82%
Deep Track Capital LP
6.38%
BlackRock Institutional Trust Company, N.A.
6.19%
Other
49.97%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
37.53%
Hedge Fund
27.96%
Investment Advisor
25.07%
Venture Capital
15.60%
Research Firm
2.18%
Foundation
0.79%
Individual Investor
0.62%
Bank and Trust
0.44%
Pension Fund
0.26%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
413
161.35M
110.53%
+5.77M
2025Q1
438
159.25M
109.27%
+2.99M
2024Q4
410
127.02M
92.80%
-4.94M
2024Q3
400
110.52M
105.30%
-20.72M
2024Q2
393
109.45M
113.05%
-19.16M
2024Q1
388
104.01M
113.08%
-21.73M
2023Q4
375
99.22M
108.37%
+5.43M
2023Q3
350
77.31M
106.51%
-14.51M
2023Q2
321
82.01M
116.66%
-275.98K
2023Q1
292
75.33M
112.27%
+21.64M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Janus Henderson Investors
20.46M
14.02%
+371.83K
+1.85%
Mar 31, 2025
RA Capital Management, LP
19.89M
13.62%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
14.34M
9.82%
+4.13M
+40.50%
Mar 31, 2025
Deep Track Capital LP
9.32M
6.38%
+2.84M
+43.81%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.03M
6.19%
+1.98M
+28.00%
Mar 31, 2025
The Vanguard Group, Inc.
7.14M
4.89%
+1.47M
+25.85%
Mar 31, 2025
Avoro Capital Advisors LLC
6.35M
4.35%
+2.25M
+54.88%
Mar 31, 2025
Citadel Advisors LLC
5.09M
3.48%
+356.98K
+7.55%
Mar 31, 2025
Pictet Asset Management Ltd.
4.20M
2.88%
+1.20M
+39.84%
Mar 31, 2025
State Street Global Advisors (US)
4.03M
2.76%
+1.09M
+36.84%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
0.92%
Harbor Health Care ETF
0.65%
First Trust Innovation Leaders ETF
0.55%
SPDR S&P Biotech ETF
0.3%
iShares Micro-Cap ETF
0.28%
Inspire Small/Mid Cap ESG ETF
0.26%
Direxion Daily S&P Biotech Bull 3X Shares
0.17%
Invesco Nasdaq Biotechnology ETF
0.16%
ProShares Ultra Nasdaq Biotechnology
0.16%
iShares Biotechnology ETF
0.14%
Ver Mais
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.92%
Harbor Health Care ETF
Proporção0.65%
First Trust Innovation Leaders ETF
Proporção0.55%
SPDR S&P Biotech ETF
Proporção0.3%
iShares Micro-Cap ETF
Proporção0.28%
Inspire Small/Mid Cap ESG ETF
Proporção0.26%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.17%
Invesco Nasdaq Biotechnology ETF
Proporção0.16%
ProShares Ultra Nasdaq Biotechnology
Proporção0.16%
iShares Biotechnology ETF
Proporção0.14%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
